Bortezomib induces autophagic death in proliferating human endothelial cells

Daniela Belloni, Lorenzo Veschini, Chiara Foglieni, Giacomo Dell'Antonio, Federico Caligaris-Cappio, Marina Ferrarini, Elisabetta Ferrero

Research output: Contribution to journalArticle

Abstract

The proteasome inhibitor Bortezomib has been approved for the treatment of relapsed/refractory multiple myeloma (MM), thanks to its ability to induce MM cell apoptosis. Moreover, Bortezomib has antiangiogenic properties. We report that endothelial cells (EC) exposed to Bortezomib undergo death to an extent that depends strictly on their activation state. Indeed, while quiescent EC are resistant to Bortezomib, the drug results maximally toxic in EC switched toward angiogenesis with FGF, and exerts a moderate effect on subconfluent HUVEC. Moreover, EC activation state deeply influences the death pathway elicited by Bortezomib: after treatment, angiogenesis-triggered EC display typical features of apoptosis. Conversely, death of subconfluent EC is preceded by ROS generation and signs typical of autophagy, including intense cytoplasmic vacuolization with evidence of autophagosomes at electron microscopy, and conversion of the cytosolic MAP LC3 I form toward the autophagosome-associated LC3 II form. Treatment with the specific autophagy inhibitor 3-MA prevents both LC3 I/LC3 II conversion and HUVEC cell death. Finally, early removal of Bortezomib is accompanied by the recovery of cell shape and viability. These findings strongly suggest that Bortezomib induces either apoptosis or autophagy in EC; interfering with the autophagic response may potentiate the antiangiogenic effect of the drug.

Original languageEnglish
Pages (from-to)1010-1018
Number of pages9
JournalExperimental Cell Research
Volume316
Issue number6
DOIs
Publication statusPublished - Apr 1 2010

Keywords

  • Antiangiogenesis
  • Apoptosis
  • Autophagy
  • Bortezomib
  • Endothelial cells

ASJC Scopus subject areas

  • Cell Biology

Fingerprint Dive into the research topics of 'Bortezomib induces autophagic death in proliferating human endothelial cells'. Together they form a unique fingerprint.

  • Cite this